Skip to main content
European Commission logo
polski polski
CORDIS - Wyniki badań wspieranych przez UE
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary
Zawartość zarchiwizowana w dniu 2024-05-24

Clostridial-directed enzyme prodrug therapy (cdept): a novel approach to cancer treatment.

Cel

Current systems for delivering therapeutic genes to tumours suffer from a number of serious deficiencies, most notably a lack of specificity for cancer cells. Here we propose an innovative solution to the problem based on the use of the spores of a harmless, non-pathogenic Clostridium species, Clostridium acetobutylicum. Intravenously injected clostridia spores localise to, and exclusively germinate in, the hypoxic regions of solid tumours. The spores are incapable of germinating in healthy tissue. We will engineer this harmless organism such that it produces a variety of prod rug-converting enzymes and assess their anti-tumour effects in a rat tumour model. New, more efficient enzymes and prod rugs will be developed. To increase safety, the clostridia host will be derivative such that it cannot speculate outside of the confines of the laboratory "flask".

Zaproszenie do składania wniosków

Data not available

System finansowania

CSC - Cost-sharing contracts

Koordynator

UNIVERSITY OF NOTTINGHAM
Wkład UE
Brak danych
Adres
Queen's Medical Centre - University Hospital
NG7 2UH NOTTINGHAM
Zjednoczone Królestwo

Zobacz na mapie

Koszt całkowity
Brak danych

Uczestnicy (4)